secwatch.observer — SEC 8-K summary
======================================

Issuer:     CVRx, Inc. (CVRX)
CIK:        0001235912
Form:       8-K
Filed at:   2022-07-28T23:59:59+00:00
Accession:  0001104659-22-083664
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

CVRx Q2 revenue $5.0M (+61% YoY); HF revenue up 90% in US; FY guidance raised
-----------------------------------------------------------------------------

- Revenue $5.0M (+61% YoY), US HF revenue $3.8M (+90% YoY) driven by territory expansion.
- Active US implanting centers reached 71 (+27% QoQ); sales territories grew to 20 from 8 a year ago.
- Net loss narrowed to $11.1M ($0.54/shr) from $17.7M; cash $121.3M at quarter end.
- FY2022 revenue guidance raised lower end to $20.5M (range $20.5-$23.0M); gross margin guidance 75-76%.
- Received FDA approval for new tablet programmer and MR conditional labeling for Barostim.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1235912/000110465922083664/0001104659-22-083664-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1235912/000110465922083664/tm2221895d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-22-083664

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer